Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
We want to learn more about the side effect profile of both Technetium Tc 99m P2045 and
Rhenium Re 188 P2045 and will do that by observing you closely after you receive the drug
and by conducting multiple tests, as well as by asking you how you feel. We want to also
learn if there is any benefit, in terms of lung cancer tumor reduction, as a result of
treatment with Rhenium Re 188 P2045.
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer
HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose of Rhenium 188 P2045
Bayer Study Director
United States: Food and Drug Administration
|Bettendorf, Iowa 52722|
|Baltimore, Maryland 21287|